A recent high-throughput screening platform for polycystic kidney disease drug discovery, utilising both murine and human ADPKD models, has also identified HDAC inhibitors as having differential responses between Pkd1 mutant and wildtype cells [65]. The gene discussed is HDAC9; the disease is polycystic kidney disease.